NVO market-structure snapshot

$NVO: multi-source stock research

NOVO NORDISK A/S

MARKET STRUCTURE

Latest close on July 27, 2026: $49.56 (+1.6% on the latest daily bar).

HMA21 / HMA55: $49.23 / $50.86. 200DMA: $47.10.

Relative volume: 0.38x the 20-day average.

Nearest support/watch zone: $48.82.

Nearest resistance/watch zone: $49.96.

Price is above the 200DMA, so the long-term trend reference is supportive.

FUNDAMENTALS AND VALUATION

Latest comparable filing period: latest period.

Valuation snapshot: trailing P/E 11.9x; forward P/E 15.2x; EV/EBITDA 2.0x; P/S 0.7x.

Read-through:
• forward P/E is above trailing P/E, implying softer expected earnings

RECENT INSTITUTIONAL RESEARCH

• 2026-07-09 — The GLP-1 drug market feast continues, with weight loss and hypoglycemic dual-wheel drive sales exploding (Nomura)

Nomura Securities released an anchor report in the GLP-1 field, pointing out that the market’s “harvest period” continues.

Data show that in the first quarter of 2026, sales of Semaglutide (total Novo Nordisk product line) reached US$21.284 billion, and sales of Tirzepatide (total Eli Lilly product line) reached US$3.741 billion, with year-on-year growth rates both maintaining above 50%.

In the weight loss market, the competition between Wegovy and Zepbound is fierce, with Q1 2026 sales of US$3.3 billion and US$4.1 billion respectively.

BOTTOM LINE

The technical structure is mixed.

WHAT TO WATCH

• Holding above HMA21 near $49.23 would preserve the short-term structure.
• A close below the nearby support zone around $48.82 would weaken the setup.
• Whether the operating milestones identified in recent institutional research become measurable disclosures.

Research and technical observation only; not a trade recommendation.

#Stocks #Fundamentals #TechnicalAnalysis #NVO